CMHC to highlight developments in cardiometabolic disease prevention, management
Click Here to Manage Email Alerts
Experts across the spectrum of cardiovascular disease, diabetes and obesity will come together for the 14th annual Cardiometabolic Health Congress to discuss evolving science and clinical practice advances in the prevention and management of cardiometabolic diseases.
The meeting will take place from Friday to Sunday at the Marriott Marquis in Chicago. A preconference cardiometabolic tech summit will take place Thursday, chaired by Endocrine Today Editorial Board Member Anne L. Peters, MD.
“There are two aspects of this meeting that are worthy of promoting,” Robert H. Eckel, MD, professor of medicine in the division of endocrinology, metabolism, diabetes and cardiology, Charles A. Boettcher II Chair in Atherosclerosis at the University of Colorado Denver Anschutz Medical Center and director of the lipid clinic at University of Colorado Hospital in Aurora, told Healio. “The first is the broad-based coverage of all components of the cardiometabolic syndrome. This meeting touches all of the points we are concerned about for our patients with cardiometabolic risk or cardiometabolic disease. The second is takeaway messages are based on current evidence and recent trials that are applicable to day-to-day patient management. In general, the audience here is a fairly sophisticated one. The quality of the speakers and the content allows them to be updated in a very effective and educational manner.”
CMHC is the largest U.S.-based, multidisciplinary conference that is solely focused on the management of cardiometabolic risk and the prevention of CV and metabolic disease. The meeting targets a broad range of health care professionals, including cardiologists, endocrinologists, primary care physicians, internal medicine physicians, nurse practitioners, physician assistants and dietitians, among others.
Attendees can expect to catch up on what was a big year in cardiometabolic news, according to organizers, including much buzzed about developments in treatments for heart failure and kidney disease.
“From last year to this year, a lot has happened,” Christie M. Ballantyne, MD, FACC, FACP, FAHA, FNLA, professor of medicine, chief of the section of cardiovascular research and director of the Center for Cardiovascular Disease Prevention at Baylor College of Medicine, told Healio. “The area of diabetes continues to be exciting with new data. We’ve gone from lowering glucose to learning these therapies also have an impact on CVD. There are a lot of exciting data on SGLT2 inhibitors, including the most recent trial showing a reduction in HF in people without diabetes. That is a paradigm shift. Also news with GLP-1 receptor agonists in reducing atherosclerotic risk. There is a lot of movement in that area and it is exciting.”
The CMHC 2019 agenda focuses on four main sessions: Diabetes Management, Lipid Management, Hypertension/HF Management, and Obesity/Lifestyle Management. Case discussions will be held within each session of the meeting and related posters will be on display in the exhibit hall.
Conference highlights
The meeting offers talks on a wide variety of topics:
- The conference’s popular FDA update and late-breaking trials session takes place Friday, with expert discussion from Eckel as well as Cardiology Today Editorial Board Member Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital and Harvard Medical School; Cardiology Today Editorial Board Member Keith C. Ferdinand, MD, of Tulane University; and Jay S. Skyler, MD, from University of Miami.
- Daniel J. Drucker, MD, will give the meeting’s keynote presentation on GLP-1 receptor agonists and the pleiotropic effects for cardiorenal protection on Friday.
- Irl B. Hirsch, MD, will hold a workshop on navigating insulin access and cost on Friday.
- A panel of experts will discuss challenging lipid management cases and how to address the “gaps,” including Kim K. Birtcher, PharmD, Leslie Cho, MD, Eckel and Cardiology Today Editorial Board Member Margo B. Minissian, PhD, ACNP, on Saturday.
- Aldo Peixoto, MD, Raymond R. Townsend, MD and Cardiology Today Editorial Board Member Michael A. Weber, MD, will discuss the latest hypertension guidelines on Saturday.
- Christos S. Mantzoros, MD, DSc, will highlight the latest developments on fatty liver disease in a session titled “NASH in a Dash” on Sunday.
Interdisciplinary coverage
“Attendees get the latest information in a short period of time on the treatment of cardiometabolic disease,” Ballantyne said. “People go to a diabetes meeting or a lipid meeting or a big cardiology meeting — but the same patients have all of these problems. So, we brought together an outstanding group of clinicians and researchers for an interdisciplinary conference focused on providing optimal care for the patient with cardiometabolic risk factors.”
Healio will provide live coverage from CMHC 2019, including reports on the sessions described above and others, on-site video interviews and much more. For more information on the CMHC agenda and registration, visit www.cardiometabolichealth.org. – by Regina Schaffer
Disclosures: Healio, Cardiology Today and Endocrine Today are media partners of CHMC. Ballantyne and Eckel are co-chairs of CMHC.